IPKat: Further analysis of Generics (t/a Mylan) v Yeda and Teva

No items found.
​
July 18, 2012
No items found.
Table of contents
  • Toc Heading
  • Toc Heading

In addition to an earlier summary by Darren Smyth of the ruling in Generics (t/a Mylan) v Yeda and Teva, Darren has provided further analysis for the IPKat.

Darren's article looks at the issue of the interpretation and clarity of two features in the patent claims.

The case relates to a European patent owned by Yeda (for which Teva is exclusive licensee) for Teva’s glatiramer acetate product marketed under the trademark Copaxone.

Recent Case Reports

See all Case Reports

Transfer of costs application from Court of Appeal to Court of First Instance rejected
22 April 2026
The UPC Court of Appeal ruled that it lacks jurisdiction to assess costs applications and confirmed they must be filed at the Court of First Instance, rejecting a transfer request in Rematec v Europe Forestry.
​
Revocation of an independent claim does not automatically affect the validity of unchallenged independent claims
21 April 2026
In Emporia v Seoul Viosys, the UPC Central Division confirmed that the revocation of an independent claim does not automatically affect the validity of unchallenged claims. The decision underscores the importance of challenging all relevant claims where full patent revocation is sought.
​
Seriously deficient disclosure process not sufficient to reopen costs order - Cabo v MGA
08 April 2026
A High Court decision highlighting the consequences of inadequate disclosure searches under PD57AD and reaffirming that costs orders are final, even where later failures come to light.
​